From: Preclinical evaluation of new GRPR-antagonists with improved metabolic stability for radiotheranostic use in oncology
Radioligand
Control
vs. ref
Between groups
+ Entresto®
[99mTc]DB15
76 ± 2%
ns
83 ± 2% (PA)
[111In]In-AU-SAR-M1
69 ± 2%
*
**
84 ± 7%
[111In]In-AU-SAR-M2
72 ± 3%
***
93.5 ± 0.8%
[111In]In-AU-SAR-M3
67 ± 3%
****
91 ± 1%